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Abstract 
Pregnancy-related acute kidney injury (AKI) may be associated with significant morbidity 
and mortality in young and often otherwise healthy women. We conducted a retrospective 
cohort study of all consecutive pregnancies between 1997 and 2011 in Ontario and describe 
the incidence, characteristics, and outcomes of AKI treated with dialysis (AKI-D) during 
pregnancy or within 12 weeks postpartum. Of 1,918,789 pregnancies, 188 were complicated 
by AKI-D (incidence proportion: 1 per 10,000, 95% confidence interval 0.8 to 1.1). Eight 
women died (4.3% versus 0.01% in the general population) and seven (3.9%) survivors 
remained dialysis-dependent four months after delivery. The presence of AKI-D was 
associated with several maternal complications as well as low birth weight, small for 
gestational age, and preterm birth among infants, although there were no stillbirths and fewer 
than five neonatal deaths in affected pregnancies. In conclusion, AKI-D in pregnancy is rare. 
Most affected women and their babies have good short-term outcomes. 
Keywords 
Administrative data, health outcomes, retrospective cohort study, pregnancy, acute kidney 
injury, dialysis 
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Glossary of Terms 
Acidosis – increased acidity in the blood or body tissue 
Acute tubular necrosis – kidney failure caused by damage to the tubules (in the kidney), often 
caused by decreased blood flow 
Alkalosis – increased alkalinity in the blood or body tissue 
Aminoaciduria – excessive excretion of amino acids in the urine 
Calyces – a system of ducts in the kidneys that carry urine  
Cardiogenic shock – shock resulting from heart failure 
Chorioamnionitis – inflammation of the fetal membranes, caused by infection 
Creatinine – a muscle breakdown product that is filtered by the kidneys and excreted in the 
urine 
Edema – swelling caused by excess fluid in body tissues 
Endomyometritis – inflammation of the endometrium, caused by an infection 
Glomerulonephritis – inflammation of the glomerulus (in the kidney), often caused by an 
immune response 
Glomerulus – a cluster of small blood vessels involved in filtering waste products from the 
blood 
Glucosuria – excessive excretion of glucose in the urine 
Gravid – pregnant 
Hydronephrosis – kidney swelling due to urine outflow obstruction 
Hyperfiltration – increased glomerular filtration rate  
 xiii 
 
Hyperkalemia – abnormally high level of potassium in the blood 
Hypokalemia – abnormally low level of potassium in the blood 
Hyponatremia – abnormally low level of sodium in the blood 
Interstitial nephritis – inflammation of the spaces between the tubules (in the kidney), often 
caused by an immune response 
Inulin – a small, inert polysaccharide molecule that is used to measure kidney function 
Ischemia – inadequate blood supply to an organ 
Lupus nephritis – inflammation of the kidney, caused by systemic lupus erythematosus 
Microangiopathic hemolytic anemia – loss of red blood cells through destruction from 
passage through small, partially occluded, blood vessels 
Nulliparous – no history of pregnancy resulting in childbirth 
Polyhydramnios – excessive amniotic fluid in the amniotic sac 
Preeclampsia – a condition characterized by high blood pressure and proteinuria in 
pregnancy 
Proteinuria – excessive excretion of proteins in the urine 
Pyelonephritis – inflammation of the kidney, caused by infection 
Renal cortical necrosis – a rare cause of kidney failure caused by decreased blood flow to the 
kidney 
Thrombocytopenia – abnormally low platelets in the blood 
Uremia – a clinical syndrome produced by accumulation of toxins due to kidney failure 
Vasoconstriction – constriction of blood vessels, which increases blood pressure 
Vasodilation – dilatation of blood vessels, which decreases blood pressure 
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Chapter 1  
1 Introduction 
1.1 Background and Overview 
Pregnancy-related acute kidney injury (AKI) is associated with significant morbidity and 
mortality in young and often otherwise healthy women.1,2 Since the 1960s, the incidence 
of pregnancy-related AKI in developed countries has declined from 1 in 3,000 to 
approximately 1 in 18,000.1 This trend has been closely linked to improved obstetrical 
care and dramatic reductions in first-trimester AKI attributable to septic abortions.3 
However, these trends are less relevant in contemporary populations. The changing risk 
profile of pregnant North American women includes lower parity, older age, higher body 
mass index, and greater comorbidities such as hypertension, diabetes mellitus, and 
chronic kidney disease, as well as increased use of reproductive technologies resulting in 
multifetal gestations.4–8 These changes may have a unique impact on the incidence and 
outcomes of pregnancy-related AKI.  
We reviewed the literature to better understand kidney function and AKI in pregnancy, 
and to identify knowledge gaps for further study. We conducted the present study to 
determine the incidence, characteristics, and outcomes of the most severe cases of AKI in 
pregnancy, namely those treated with dialysis, in a contemporary cohort of 1.9 million 
pregnancies in Ontario, Canada. 
 
2 
 
Chapter 2  
2 Literature Review 
2.1 The Normal Kidney 
2.1.1 Brief Overview of Kidney Function 
The kidney is a vital organ and has several key functions. These include (1) excretion of 
waste products of metabolism such as urea, creatinine, and uric acid, (2) regulation of 
fluid and electrolytes, including sodium, potassium, and hydrogen, and (3) secretion of 
hormones that regulate local and systemic hemodynamics, red cell production, and 
mineral metabolism.9  
2.1.2 Measurement of Kidney Function 
The glomerular filtration rate is used to assess the level of kidney function and is equal to 
the sum of the filtration rates in all functioning nephrons (filtration units in the kidney).9 
This can be measured by timing urinary clearance of inulin, a physiologically inert 
substance that is freely filtered by the glomerulus without being secreted, reabsorbed, 
synthesized, or metabolized by the kidney.10 However, this method is complex and even 
though less cumbersome methods for measuring clearance are available (using alternative 
filtration markers and plasma clearance), it has largely been replaced by estimations of 
glomerular filtration rate using creatinine clearance or estimation equations such as the 
Cockcroft-Gault equation,11 the Modification of Diet in Renal Disease (MDRD) study 
equations,12 and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation.13 All of these equations are dependent on serum creatinine concentration, with 
higher serum creatinine concentrations translating to lower estimated glomerular 
filtration rates.  
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2.2 The Kidney in Pregnancy 
2.2.1 Brief Overview of Physiologic Changes in Pregnancy 
Several anatomic and physiologic changes occur in the kidney and urinary tract to 
accommodate pregnancy. Understanding these changes is essential to accurate 
recognition and management of AKI during pregnancy and the postpartum period. 
Both kidney length and volume change during pregnancy. Kidney volume increases by 
up to 30% as a result of increases in vascular and interstitial spaces, and kidney length 
increases by 1-1.5 cm with dilatation of the urinary collecting system.14 Dilatation of the 
renal pelvises, calyceal systems, and ureters occurs as early as 6 weeks gestation and is 
typically more pronounced on the right side.15 Hydronephrosis occurs in up to 80% of 
women.15 Urinary stasis in this setting can also predispose women to ascending urinary 
tract infections such as pyelonephritis.15 
Several hemodynamic changes also occur within the maternal circulation that contribute 
to hyperfiltration, the hallmark of healthy adaptation to pregnancy. These include 
vasodilation, decreased systemic vascular resistance, and decreased arterial pressure, 
which nadirs between 18 and 24 weeks gestation.16 Plasma volume increases by 
approximately 1 L and total body water increases by 6-8 L (primarily in the extracellular 
compartment), which can result in edema during pregnancy.17,18 Cardiac output increases 
due to decreased afterload in this setting.16 Coinciding with these changes, renal plasma 
flow increases by 80% and glomerular filtration rate increases by 40-60% by the second 
half of pregnancy, clinically manifesting as a decrease in circulating creatinine, urea, and 
uric acid.17 Renal plasma flow falls rapidly after 36 weeks gestation, followed by 
normalization of glomerular filtration rate.19  
In addition to the effect of hyperfiltration, altered tubular reabsorption is likely also 
responsible for increased levels of urinary protein,20 glucose,21 and amino acids22 during 
pregnancy. However, in limited studies designed primarily to determine mechanisms, 
results are inconclusive and the clinical relevance of glucosuria and aminoaciduria in 
pregnancy is not known. While the upper limit of normal for proteinuria in pregnancy 
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cited in obstetrical guidelines is 300 mg/24-hour period, double the upper limit of normal 
for the non-gravid state, significant proteinuria in pregnancy is not considered adaptive.23 
Several other physiologic changes occur during pregnancy that result in mild 
hyponatremia,24 mild hypokalemia,25 and chronic respiratory alkalosis.26 These, and other 
anatomic and physiologic changes, typically return to pre-pregnancy state within a few 
weeks postpartum. 
2.2.2 Measurement of Kidney Function in Pregnancy 
Hyperfiltration in pregnancy results in a physiologic decrease in serum creatinine 
concentration by an average of 35 micromol/L.17 This renders estimations of glomerular 
filtration rate based on serum creatinine concentration inaccurate. The Cockcroft-Gault 
equation has been shown to underestimate glomerular filtration by 25% in 23% of cases 
studied.27 The MDRD equation underestimated glomerular filtration by 25% in 61% of 
cases studied.27 The CKD-EPI equation, which was developed to provide a more accurate 
estimate of glomerular filtration among patients with higher glomerular filtration rates,28 
has not been assessed in pregnancy. Measurement of creatinine clearance with a 24-hour 
urine collection is also imprecise during pregnancy due to the delay between urine 
formation and collection that results from urinary stasis with dilatation of the lower 
urinary tract.29 Considering these limitations, assessment of kidney function in pregnancy 
is restricted to examining trends in serum creatinine concentration, the interpretation of 
which is also dependent on the presence of baseline measures of serum creatinine prior to 
pregnancy. 
2.3 Acute Kidney Injury 
2.3.1 Definition of Acute Kidney Injury in the General Population 
AKI is a sudden loss of kidney function, resulting in the retention of urea and other waste 
products, and dysregulation of fluid and electrolytes.30 This can result from specific 
diseases of the kidney (e.g., interstitial nephritis, glomerulonephritis) or extrarenal 
pathology (e.g. dehydration, heart failure, sepsis, obstruction).30 In severe cases, this 
manifests as metabolic acidosis, electrolyte abnormalities, fluid retention, hypertension, 
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in glomerular filtration rate among women with normal or near normal values at baseline, 
may not be appreciated at the time of presentation using these criteria.37 Therefore, 
although a wide range of criteria have been used to define pregnancy-related AKI in 
previous studies, including RIFLE criteria38 and hospital diagnosis codes,2,39,40 these 
should be expected to underestimate its true incidence. Even in the general population, 
hospital diagnosis codes for AKI lack sensitivity.41 At this point, the diagnosis of AKI in 
pregnancy is primarily a clinical one, dependent on careful interpretation of serum 
creatinine values in the context of known baseline measures of kidney function by an 
astute clinician.  
2.3.3 Role of Dialysis in Acute Kidney Injury 
In both non-pregnant and pregnant populations, management of AKI is supportive and is 
focused on identification and treatment of the underlying cause (which, depending on the 
cause in pregnancy, may necessitate early delivery of the fetus).23,42 However, if 
conservative therapy fails to control complications such as acidosis, hyperkalemia, 
volume overload, or symptomatic uremia, dialysis may be indicated.34,42 Dialysis is a 
process whereby blood is removed from the body and circulated through an 
extracorporeal fluid circuit, then returned to the patient. Waste products and excess fluid 
are removed from the blood via diffusion (movement of solute by concentration gradient) 
and ultrafiltration (movement of fluid and solute by pressure gradient).43 There are 
several risks associated with this process, including hypotension, arrhythmia, infection, 
and bleeding, so clinicians tend to delay initiation of dialysis in cases where they suspect 
the patient will recover on their own and complications can be managed with medical 
therapy.34,43 Although the optimal timing, modality, and dose of dialysis for AKI has not 
been determined in any population, these clinical indications are universally recognized 
as indicators of high disease severity and are consistent with the recommendations 
provided in the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice 
Guideline for AKI.34,42 Literature on maintenance of pregnancy in the setting of end-stage 
kidney disease suggests that there may be a role for early initiation of intensive 
hemodialysis to minimize maternal complications and fetal risks from uremia (such as 
polyhydramnios, preterm birth, premature rupture of membranes, and developmental 
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delay),44–46 however there is no evidence that this strategy is being adopted for severe 
AKI in pregnancy.42  
2.4 Epidemiology of Acute Kidney Injury 
2.4.1 Epidemiology of Acute Kidney Injury in the General Population 
The incidence rate of AKI requiring dialysis in the general population is 24.4 per 100,000 
person-years and is increasing by an average of 10% per year.36,47 In-hospital mortality is 
approximately 60%.48–50 Among those who survive, as many as 15% remain on dialysis 
at the time of discharge.49,51  
2.4.2 Epidemiology of Acute Kidney Injury in Pregnant Populations 
The true incidence of AKI in pregnancy is difficult to determine due to the inconsistency 
of diagnostic criteria used to define AKI and varies considerably across populations 
depending on demographics and standards of care. However, several general 
epidemiologic trends can be established from existing studies.  
Based on data from several diverse populations since the 1960s, the incidence proportion 
of AKI in pregnancy has declined dramatically from 1 in 3,000 to 1 in 15,000-20,000 
worldwide.1,52–55 Similarly, the proportion of all AKI cases accounted for by pregnancy-
related causes has dropped from 20-40% to 2-10%.1,53,54 Short-term maternal morbidity 
after pregnancy-related AKI and dialysis dependence among survivors has also nearly 
disappeared, previously affecting as many as 30% and 11% of cases respectively. These 
trends have been closely linked to improved obstetrical care in developed countries and 
dramatic reductions in first-trimester AKI attributable to fewer septic abortions with the 
legalization of abortion.1   
Studies that have examined secular trends of AKI in pregnancy in contemporary North 
American populations have demonstrated a paradoxical increase in incidence of AKI 
defined by hospital diagnosis codes (Table 2)39,40,56 which is in keeping with the trends 
observed in the general population using serum creatinine-based definitions of AKI.36,47 
Callaghan et al. reported a significant increase in the incidence proportion of AKI in 
pregnancy in the United States between 1998 and 2008, from 2.3 to 4.5 per 10,000 
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deliveries (P < 0.05).40 A similar trend was observed in Canada where the incidence 
proportion of AKI in pregnancy increased from 1.6 to 2.7 per 10,000 deliveries between 
2003 and 2010 (P < 0.05).39,56 This temporal increase was restricted to pregnancies 
complicated by hypertensive disorders and was especially pronounced among women 
with gestational hypertension and proteinuria (i.e. preeclampsia).56 These trends also 
correspond to increases in the rate of deliveries among women with pre-existing medical 
conditions such as hypertension, diabetes mellitus, and chronic kidney disease (known 
risk factors for preeclampsia) and those with complications such as preeclampsia and 
postpartum hemorrhage noted in other population-based studies.7  
Table 2: Contemporary population-based studies of acute kidney injury in 
pregnancy 
Study 
(Publication 
Date) 
Population 
(Years)  AKI Definition 
Incidence 
Proportion 
Associated 
Conditions 
Liu et al.39 
(2010) 
All hospital 
deliveries in 
Canada (except 
Quebec) 
(2003-2007) 
ICD-10 diagnosis 
codes for AKI 
(Canadian Institute 
for Health 
Information – 
Discharge abstract 
database) 
1.6 to 2.3 
cases/10,000 
deliveries from 
2003 to 2007 
Not reported 
  
CCI procedure codes 
for dialysis (Canadian 
Institute for Health 
Information – 
Discharge abstract 
database) 
0.4 to 0.4 
cases/10,000 
deliveries from 
2003 to 2007 
Not reported 
Callaghan et 
al.40 (2012) 
All delivery and 
postpartum 
hospitalizations 
in a stratified 
sample of 
community 
hospitals in the 
United States 
(1998-2009) 
ICD-9 diagnosis 
codes for AKI 
2.3 to 4.5 
cases/10,000 
deliveries from 
1998 to 2009 
Not reported 
Mehrabadi et 
al.56 (2014) 
All hospital 
deliveries in 
Canada (except 
Quebec)  
(2003-2011) 
ICD-10 diagnosis 
codes for AKI 
(Canadian Institute 
for Health 
Information – 
Discharge abstract 
database) 
1.6 to 2.7 
cases/10,000 
deliveries from 
2003 to 2010 
Age >35, 
nulliparity, 
multifetal gestation, 
hypertension, 
diabetes, 
preeclampsia, 
postpartum 
hemorrhage, sepsis, 
cardiac failure, 
caesarean section 
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CCI procedure codes 
for dialysis (Canadian 
Institute for Health 
Information – 
Discharge abstract 
database) 
10.4% to 7.6% of 
AKI cases from 
2003 to 2010 
Not reported 
2.5 Etiology of Acute Kidney Injury in Pregnancy 
Clinical investigation for the cause of AKI in pregnancy is the same as in the non-
pregnant population, which includes consideration of pre-renal, renal, and post-renal 
etiologies.42 However, there are several conditions known to precipitate AKI that are 
either unique to pregnancy or worsened by the gravid state. Unfortunately, there are 
limited data on the incidence, risk factors, and outcomes of these conditions, including 
the associated risk of AKI. The following three sections elaborate on three main causes of 
AKI in pregnancy that can occur in the setting of many common medical or surgical 
complications of pregnancy. However, much of this information is based on known 
pathophysiologic mechanisms, rather than population-based studies designed to assess 
the risk of AKI in these settings. 
2.5.1 Ischemic Injury 
Volume depletion from any cause can precipitate AKI in pregnancy through pre-renal 
ischemia or acute tubular necrosis. Prior to 20 weeks gestation, this may be due to 
hyperemesis gravidarum, a condition defined by refractory nausea and vomiting 
accompanied by weight loss in excess of 5% of pre-pregnancy body weight, or obstetrical 
hemorrhage due to a spontaneous or induced abortion.42 Later in pregnancy, cardiogenic 
shock as a result of an amniotic fluid embolism, obstetrical hemorrhage from placental 
abruption, or postpartum hemorrhage are more common.42 Sepsis due to 
chorioamnionitis, endomyometritis, or pyelonephritis can lead to AKI in pregnancy 
through similar mechanisms.42,57 Renal cortical necrosis can also occur in these settings, 
however this is now almost exclusively limited to developing countries where access to 
prompt obstetrical care is limited.42,58 
10 
 
2.5.2 Hypertensive Disorders of Pregnancy 
Preeclampsia refers to the new onset of hypertension and either proteinuria or end-organ 
dysfunction after 20 weeks gestation.23 The frequency of preeclampsia ranges from 2% to 
7% in healthy nulliparous women and increases substantially in women with advanced 
maternal age, multifetal gestation, chronic hypertension, diabetes mellitus, and chronic 
kidney disease.59,60 Preeclampsia is the leading cause of maternal morbidity and mortality 
worldwide and is the most common cause of AKI during pregnancy.61 Although most 
women experience only minor transient increases in serum creatinine; when accompanied 
by features of HELLP syndrome (defined by the presence of hemolysis, low platelet 
count, and elevated liver enzymes), AKI has been reported in 3-15% of cases.62,63 In 
addition to the direct effect of preeclampsia on renal function via endothelial injury, 
secondary effects of intravascular volume depletion, vasoconstriction, and activation of 
inflammatory and coagulation cascades in these settings can increase the risk of kidney 
failure in pregnancy.63  
2.5.3 Thrombotic Microangiopathy 
Although much less common, thrombotic microangiopathy is another important cause of 
AKI in pregnancy; which, like preeclampsia, typically presents after 20 weeks gestation. 
Thrombotic microangiopathy is a pathological process characterized by microangiopathic 
hemolytic anemia, thrombocytopenia, and variable signs of organ injury from endothelial 
damage and thrombosis.64 Thrombotic microangiopathy is a defining feature of 
thrombotic thrombocytopenic purpura (TTP), a condition caused by a congenital or 
acquired deficiency in ADAMTS13 (A Disintegrin And Metalloprotease with a 
ThromboSpondin type 1 motif, member 13, an enzyme that works to minimize 
microvascular thrombosis by cleaving complexes formed by von Willebrand factor and 
platelets).65 However, thrombotic microangiopathies may be caused by other 
mechanisms, including enteric infection with Shiga toxin (known as hemolytic uremic 
syndrome [HUS]), drug-mediated toxicity or immune reaction, and complement 
dysregulation (known as atypical HUS) or may be the manifestation of several other 
underlying disorders in up to 60% of cases.65 Although thrombotic microangiopathy 
occurs in only 1 in 25,000 pregnancies, pregnancy accounts for 10-25% of cases of 
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thrombotic microangiopathy and is a known trigger for ADAMTS13 deficiency in TTP 
and uncontrolled complement activation in atypical HUS.66–68 AKI is most common 
among patients with atypical HUS with severe AKI requiring dialysis reported in over 
80% of cases.68    
2.6 Outcomes of Acute Kidney Injury in Pregnancy 
In a population-based study of hospital deliveries in Canada between 2003 and 2011, the 
proportion of pregnancies affected by AKI that required dialysis was 8.8% and maternal 
death occurred in 2.8% of cases.56 However, based on the information provided, acute 
dialysis may not have been completely captured in this study,56 and this data does not 
reflect dialysis dependence among survivors. Reports of this outcome are limited to two 
small studies from Brazil and Egypt, in which AKI was defined by treatment with 
dialysis and RIFLE criteria within admission to the intensive care unit respectively.38,69 
These studies suggest that up to 50% of women may remain dialysis dependent 
postpartum and maternal death may occur in up to 30% of cases of severe AKI.38,69 
However, these studies represent single-center experiences prone to selection biases. No 
study to-date has examined the perinatal complications associated with AKI of any 
severity in a contemporary developed population. 
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Chapter 3  
3 Rationale for Research Approach  
3.1 The Need for Research 
Several attempts have been made to understand pregnancy-related AKI in contemporary 
populations.2,38–40,56,69,70 These studies have been limited by small sample sizes,38,69 
highly selected populations,38,69,70 and use of definitions for AKI that have not been 
validated in pregnancy and in some cases might lack clinical relevance.2,39,40,56 Trends in 
older maternal age and greater chronic disease among pregnant North American women 
appear to have a negative impact on the incidence of pregnancy-related AKI in 
contemporary populations.7,56 How these trends impact the incidence, characteristics, and 
outcomes of more severe presentations of AKI, such as those treated with acute dialysis 
during pregnancy or the postpartum period, remains unclear. Small, single center studies 
suggest that maternal morbidity and mortality may still be high in these cases, while 
perinatal complications remain uncertain.38,69  
3.2 Our Research Approach 
In 2013, Ontario had a population of nearly 14 million residents with approximately 
140,000 births occurring each year over the previous 5 years (2009–2013).71,72 All 
permanent residents of Ontario receive universal access to hospital and physician services 
from a single provincial payer. Comprehensive health administrative data collected for 
this purpose is de-identified and housed in a large repository at the Institute for Clinical 
Evaluative Sciences (ICES) for the purpose of health services research.73 This data can be 
leveraged to conduct large population-based studies of health outcomes. 
We used Ontario’s health administrative data to identify all consecutive pregnancies 
between 1997 and 2011 and describe the incidence, characteristics, and outcomes of AKI 
treated with dialysis (AKI-D) during pregnancy or the postpartum period using 
administrative data from several sectors of health care.  
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3.2.1 Strengths of Ontario’s Health Administrative Data  
There are several advantages to using this data. Ontario’s health administrative databases 
are large and provide the opportunity to identify populations retrospectively with minimal 
selection bias and loss to follow-up (only by emigration out of the province, which is less 
than 0.5% per year), ensuring high generalizability.74 Access to large population-based 
cohorts through this strategy also allows researchers to examine rare events such as AKI 
in pregnancy with high statistical power, low cost, and limited time. Because data from 
several sectors of health care (vital statistics, physician services, hospital records, 
medications) can be linked, a wide range of variables can be ascertained. Many of these 
variables, including those used to study AKI in pregnancy, have proven valid in previous 
studies.75–83 In addition, because maternal hospital records can be linked to infant hospital 
records, there is a unique opportunity to examine perinatal characteristics not addressed 
in previous studies.  
3.2.2 Limitations of Ontario’s Health Administrative Data 
However, administrative data is limited by its primary purpose, which is to guide 
remuneration and resource allocation. As a result, there are information gaps in history 
and physical examination variables, laboratory data, and medication use for those under 
the age of 65.73 Further, although some administrative data codes have been validated for 
use in research, the majority have not. Many coding algorithms lack sensitivity and 
misclassification of variables can occur. This misclassification is typically ‘non-
differential’, as acquisition of data is independent of the research question and not subject 
to recall bias, and should be expected to bias of the estimate of effect towards the null 
hypothesis (Type II error) and/or result in suboptimal control of confounding variables.84 
Medical procedures are generally considered more reliable than diagnoses obtained from 
medical records given the financial incentives and processes in place to submit and 
encode data.84  
3.3 Challenges of Pregnancy Outcomes Analyses  
There are several analytic challenges to consider when conducting population-based 
pregnancy outcome studies. First, administrative data sources in Canada only capture 
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pregnancies resulting in childbirth (live or stillborn), so pregnancies resulting in a 
spontaneous or therapeutic abortion prior to 20 weeks gestation (which may occur in up 
to 25% of pregnancies) are not captured.85 Second, because women may have several 
pregnancies during the data accrual period, exposure and outcome data may be clustered 
by mother if pregnancy is used as the unit of analysis. Failure to account for this 
intracluster correlation may bias the estimate of effect towards rejecting the null 
hypothesis (Type I error).86  However, several modeling approaches may be used to 
address this.86,87 Third, because pregnancy is often the first healthcare encounter for 
women included in these studies, data on preexisting conditions may not have been 
captured in administrative data. This may result in misclassification of pre-pregnancy 
conditions as pregnancy-related if identified during prenatal care.  
Finally, while there are several conditions known to be associated with AKI in 
pregnancy,56 the relationship between pre-pregnancy maternal characteristics, medical 
complications of pregnancy, and adverse maternal and perinatal outcomes is complex. 
Many of these variables are highly correlated and there is limited data to support 
assumptions about the pathophysiologic pathway that represents the relationship between 
suspected risk factors, confounders, and outcomes, and the directionality of these 
associations. This makes it difficult to adequately control for confounding and, in some 
cases, even assign labels such as ‘exposure’ and ‘outcome’. For example, consider the 
proposed association between preeclampsia, AKI, and preterm birth highlighted in Figure 
1 (oversimplified for demonstration purposes).  
Figure 1: Potential causal pathways for the association between preeclampsia, AKI, 
and preterm birth 
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Depending on the causal pathway of interest, AKI may be a ‘mediator’ of the association 
between preeclampsia and preterm birth, a ‘confounder’ if not actually on the causal 
pathway between preeclampsia and preterm birth, or an ‘exposure’ relative to 
preeclampsia or preterm birth. Further, preterm birth could actually precede the clinical 
diagnosis of preeclampsia and/or AKI if there is an another 'exposure' (risk factor or 
characteristic) at play. This other exposure, such as the condition lupus nephritis, may act 
both as a cause of preterm birth and a risk factor for either preeclampsia, AKI, or both. 
This would reverse the sequence of identification of events, but would not necessarily 
mean that preterm birth caused preeclampsia or AKI. For this reason, the purpose of this 
study was not to establish causality, but rather to determine the direction and magnitude 
of associations in order to create a framework for physicians to better identify women at 
risk. 
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4.2 Research Framework 
In order to address these questions, we conducted a retrospective population-based cohort 
study of all consecutive pregnancies resulting in childbirth over a 15-year period (1997-
2011) in Ontario, Canada to identify incident cases of AKI-D during pregnancy or the 
postpartum period, determine the concurrent maternal complications that may be 
associated with AKI-D, and examine perinatal complications and maternal outcomes in 
relation to AKI-D. 
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Chapter 5  
5 Methods 
5.1 Design and Setting 
We conducted a retrospective population-based cohort study using linked healthcare 
databases in Ontario, Canada to study the incidence, characteristics, and outcomes of 
AKI-D in pregnancy and the postpartum period. Study conduct and reporting follow 
guidelines (STROBE) for observational studies (Appendix A).88  
5.2 Ethics 
A research ethics board at Sunnybrook Health Sciences Centre in Toronto approved the 
pre-specified protocol (Appendix B and C). However, numbers of participants were 
suppressed in the case of five or fewer participants (reported as ≤ 5) to comply with 
privacy regulations for minimizing the chance of identification of a study participant. 
5.3 Data Sources 
5.3.1 Databases 
We identified our pregnant population by childbirth and ascertained maternal and 
perinatal characteristics and outcome data from records in seven linked databases from 
the Institute of Clinical Evaluative Sciences (ICES). Vital statistics and location of 
residence were obtained from the Registered Persons Database, which contains 
demographic information for all Ontario residents ever issued a health card.73 We used 
inpatient and outpatient diagnostic and procedural information to define maternal 
characteristics and outcome data. The Canadian Institute for Health Information 
Discharge Abstract Database (CIHI-DAD) collects demographic, diagnostic, and 
procedural variables for all acute care, chronic, and day surgery admissions.73 The 
Ontario Health Insurance Plan (OHIP) database contains fee-for-service claims for 
inpatient and outpatient physician services.73 Each claim record includes information 
about the physician, service provided, and diagnostic information. Diabetic and 
hypertensive patients were identified using the Ontario Diabetes Database and the 
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Ontario Hypertension Database. These databases are derived by ICES and use a validated 
algorithm to identify diabetic and hypertensive patients based on data from CIHI-DAD 
and OHIP.76,77 Childbirths and perinatal characteristics were identified using the 
MOMBABY dataset. This is also an ICES-derived dataset that links the CIHI-DAD 
inpatient admission records of delivering mothers and their newborns.73 Maternal cause 
of death was determined from the Ontario Registrar General Death database, which 
contains information on all deaths registered in Ontario.73 Members of our research team 
have used these databases in previous studies to research health outcomes and health 
services including those related to AKI-D.89–92 Ascertainment of variables from these 
databases were complete, with minor exceptions detailed in Table 5. 
Table 5: Missing data for cohort of 1,918,789 pregnancies resulting in childbirth, 
1997 to 2011 
Database Dates Available Dates Required Dates Missing Data Affected 
     
OHIP 
 
July 1991 to 
March 2012 
April 1991 to 
March 2012 
April 1991 to 
June 1991 
Incomplete capture of pre-
pregnancy chronic kidney disease 
in the 5-years prior to pregnancy for 
childbirths between January 1997 
and March 1997. 
     
ORGD 
 
January 1990 to 
December 2009 
January 1997 to 
March 2012 
January 2010 to 
March 2012 
Missing cause of death for 
childbirths resulting in maternal 
death between January 2010 and 
March 2012. 
     
RPDB April 1990 to 
March 2012 
(Incomplete) 
 
January 1997 to 
March 2012 
January 1997 to 
March 2012 
(Selected Data) 
Missing income quintile in 9851 
(0.51%) childbirths and rural 
residence in 2488 (0.13%) 
childbirths between January 1997 
and March 2012. 
     
 
Abbreviations: OHIP, Ontario Health Insurance Plan using fee and diagnostic codes; RPDB, Registered Persons 
Database; ORGD, Ontario Registrar General Death database. 
5.3.2 Codes 
In Ontario, hospital admissions were coded using the International Classification of 
Diseases, Ninth Revision (ICD-9) (including Canadian Classification of Diagnostic, 
Therapeutic, and Surgical Procedures [CCP]) prior to April 2002 and the International 
Classification of Diseases, Tenth Revision (ICD-10) (including Classification of Health 
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Maternal Characteristics Prior to Pregnancy † 
   
Age 
 
RPDB N/A 
Neighborhood income RPDB N/A 
   
Rural residence RPDB N/A 
   
Previous pregnancy ‡ 
 
MOMBABY MOMBABY: [B_BDATE] in the infant CIHI-DAD record 
Hypertension  OHD § N/A  
 
Diabetes mellitus ODD || N/A 
 
Chronic kidney  
disease 
CIHI-DAD 
OHIP 
ICD-9: 4030, 4031, 4039, 4040, 4041, 4049, 582, 583, 580, 
581, 584, 585, 586, 587, 5880, 5888, 5889, 5937 
ICD-10: E102, E112, E132, E142, I12, I13, N08, N18, N19 
OHIP: 403, 585 
 
General practitioner 
/Family physician 
 
IPDB N/A 
Internal medicine 
specialist 
 
IPDB N/A 
Nephrologist ¶ OHIP OHIP: C132, C101, C138, G860, G323, E083, C137, C135, 
A135 
 
Maternal Complications During Pregnancy or the Postpartum Period ** 
   
Multifetal gestation MOMBABY MOMBABY: [B_MULTIPLE BIRTH] or [M_MULTIPLE 
BIRTH] in the infant/maternal CIHI-DAD record 
 
Hyperemesis 
gravidarum 
CIHI-DAD 
OHIP 
ICD-9: 64300, 64301 
ICD-10: O21001, O21003, O21009, O21101, O21103, O21109 
OHIP: 643 
 
Gestational 
hypertension 
CIHI-DAD 
 
ICD-9: 64290, 64291, 64292, 64293, 64294 
ICD-10: O13 
 
Preeclampsia  
(includes eclampsia) 
CIHI-DAD 
OHIP 
ICD-9: 64240, 64241, 64242, 64243, 64244, 64250, 64251, 
64252, 64253, 64254, 64260, 64261, 64262, 64263, 64264, 
64270, 64271, 64272, 64273, 64274 
ICD-10: O14, O15 
OHIP: 642 
 
Thrombotic 
microangiopathy †† 
CIHI-DAD 
OHIP 
ICD-9: 4466 
ICD-10: M311 
OHIP: 287 
 
Plasma exchange †† OHIP OHIP: G272, G277, G278, G290 
 
Pyelonephritis CIHI-DAD 
OHIP 
 
ICD-9: 59000, 59001, 59010, 59011, 5902, 59080, 59081, 5909 
ICD-10: N110, N111, N151, O23001, O23002, O23003, 
O23004, O23009 
OHIP: 590 
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Sepsis CIHI-DAD 
OHIP 
ICD-9: 0031, 0380, 0381, 0382, 0383, 03840, 03841, 03842, 
03843, 03844, 03849, 0388, 0389, 0545, 65930, 65931, 65933 
ICD-10: A400, A401, A402, A403, A408, A409, A410, A411, 
A412, A413, A414, A4150, A4151, A4152, A4158, A4159, 
A4180, A4188, A419, R572, O85002, O85004, O85009   
OHIP: 038 
 
Caesarean delivery CIHI-DAD ICD-9: 66970, 66971 
ICD-10: P034 
CCP: 860, 861, 862 
CCI: 5MD60AA, 5MD60CB, 5MD60CC, 5MD60CD, 
5MD60CE, 5MD60CF, 5MD60CG, 5MD60JW, 5MD60JX, 
5MD60JY, 5MD60JZ, 5MD60KA, 5MD60KB, 5MD60KC, 
5MD60KD, 5MD60KE, 5MD60KF, 5MD60KG, 5MD60KT, 
5MD60RA, 5MD60RB, 5MD60RC, 5MD60RD, 5MD60RE, 
5MD60RF, 5MD60RG, 5MD60RH 
 
Postpartum 
hemorrhage 
CIHI-DAD 
OHIP 
 
ICD-9: 66600, 66602, 66604, 66610, 66612, 66614, 66620, 
66622, 66624 
ICD-10: O72 
OHIP: 666 
 
Perinatal Complications 
   
Low birth weight MOMBABY 
 
MOMBABY: [WEIGHT] < 2500g in infant CIHI-DAD record 
 
Small for gestational 
age (includes 
intrauterine growth 
restriction) 
 
CIHI-DAD 
 
ICD-9: 65650, 65651, 65653, 76400, 76401, 76402, 76403, 
76404, 76405, 76406, 76407, 76408, 76409, 76410, 76411, 
76412, 76413, 76414, 76415, 76416, 76417, 76418, 76419, 
76490, 76491, 76492, 76493, 76494, 76495, 76496, 76497, 
76498, 76499 
ICD-10: P0590, P0591, P0599 
 
Preterm birth 
 
MOMBABY 
 
MOMBABY: [B_GESTWKS_DEL] or [M_GESTWKS_DEL] 
< 37 weeks in infant/maternal CIHI-DAD record 
ICD-9: 76500, 76501, 76502, 76503, 76504, 76505, 76506, 
76507, 76508, 76509, 76510, 76511, 76512, 76513, 76514, 
76515, 76516, 76517, 76518, 76519 
ICD-10: P070, P071, P072, P073 
OHIP: 765 
[ICD-9 and ICD-10 codes were used to define preterm birth 
when infant data from MOMBABY dataset was missing] 
 
Stillbirth MOMBABY MOMBABY: [B_STILLBIRTH] or [M_STILLBIRTH] in 
infant/maternal CIHI-DAD record 
   
Perinatal mortality MOMBABY 
 
MOMBABY: [DTHDATE] within 7 days of birth in infant 
RPDB record or [B_STILLBIRTH] or [M_STILLBIRTH] in 
infant/maternal CIHI-DAD record 
 
Neonatal death 
 
MOMBABY 
 
MOMBABY: [DTHDATE] within 28 days of birth in infant 
RPDB record 
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Abbreviations: CIHI-DAD, Canadian Institute for Health Information Discharge Abstract Database using International 
Classification of Disease, Ninth Revision (ICD-9) and Tenth Revision (ICD-10), Canadian Classification of Diagnostic, 
Therapeutic, and Surgical Procedures (CCP), and Classification of Health Interventions (CCI) codes; OHIP, Ontario 
Health Insurance Plan using fee and diagnostic codes; RPDB, Registered Persons Database; OHD, Ontario 
Hypertension Database; ODD, Ontario Diabetes Database; N/A, Not applicable. 
* Variables are defined by the presence of at least one of the listed codes unless otherwise specified. 
† Information on preexisting medical conditions and consultations was ascertained from administrative database 
codes in the five years prior to pregnancy. Age, neighborhood income, and rural residence were ascertained at time 
of delivery. 
‡ Information on previous pregnancies was available since 1991 and included all pregnancies in Ontario resulting in 
live birth or stillbirth after 20 weeks gestation. 
§ The Ontario Hypertension Database is an ICES-derived database that contains all Ontario hypertension patients 
defined by a) one hospital admission with a hypertension diagnosis, or b) an OHIP claim with a hypertension 
diagnosis followed within two years by either an OHIP claim or a hospital admission with a hypertension 
diagnosis.76 
|| The Ontario Diabetes Database is an ICES-derived database that contains all Ontario diabetes patients defined by 
the presence of at least one hospital admission with a diabetes diagnosis or an OHIP claim with a diabetes 
diagnosis.77 
¶  Restricted to physicians who also billed at least 50 dialysis codes (one per day) within one year of consultation 
service date. 
** Information on medical complications of pregnancy were ascertained from administrative database codes during 
pregnancy and the postpartum period. 
†† The variable ‘thrombotic microangiopathy treated with plasma exchange’ was defined by receipt of plasma 
exchange that falls within an admission for thrombotic microangiopathy (using CIHI-DAD codes) or within seven 
days of a diagnosis of thrombotic microangiopathy (using OHIP codes). 
 
5.3.3 Validity 
Whenever possible, we defined maternal characteristics, medical complications of 
pregnancy, and maternal and perinatal outcomes using database codes that have been 
proven feasible and reliable in prior studies. Operating characteristics for the codes used 
to define variables where validity studies exist are shown in Table 7. ICD-10 
implementation in 2002 did not significantly alter coding practices for common comorbid 
conditions used in risk assessment in Ontario.93,94 
Table 7: Operating characteristics of codes used to define variables where validity 
studies exist.  
    Operating Characteristics 
Outcome 
Codes 
Used in 
Study 
Codes 
Used in 
Validation 
Gold Standard Sn (%) 
Sp 
(%) 
PPV 
(%) 
       
Preterm birth 
 
P070  
P071 
P072 
P073 
P070 
P071 
P072 
P073 
Identification of preterm delivery as 
ascertained through chart review by 
trained personnel.75 
91.2 98.8 … 
       
Caesarean 
delivery 
P034 P034 Identification of caesarean delivery as 
ascertained through chart review by 
99.8 98.7 … 
25 
 
trained personnel.75 
       
Gestational 
hypertension 
O13 O13 Identification of gestational 
hypertension as ascertained through 
chart review by experienced 
clinicians.79,80 
10.0-
68.2 
99.6-
99.8 
… 
       
Preeclampsia 64240 
64241 
64242 
64243 
64244 
64250 
64251 
64252 
64253 
64254 
64260 
64261 
64262 
64263 
64264 
64270 
64271 
64272 
64273 
64274 
6424 Identification of ‘mild or unspecified 
preeclampsia’ on chart review by 
obstetricians using criteria 
established by the American College 
of Obstetrics and Gynecology.81 
78.4 64.3 45.3 
 6425 Identification of ‘severe 
preeclampsia’ on chart review by 
obstetricians using criteria 
established by the American College 
of Obstetrics and Gynecology.81 
66.7 85.0 84.8 
 6426 Identification of ‘eclampsia’ on chart 
review by obstetricians using criteria 
established by the American College 
of Obstetrics and Gynecology.81 
83.3 94.6 41.7 
 6425 
6426 
Identification of ‘severe preeclampsia 
and eclampsia’ on chart review by 
obstetrician.82 
100.0 100.0 100.0 
 6425 
6427 
Identification of ‘preeclampsia’ on 
chart review by experienced 
accredited record technicians or 
certified coding specialists.83 
76.0 … 94.0 
 O14 
O15 
O14 
O15 
Identification of ‘preeclampsia’ on 
chart review using a well-described 
and accepted definition.80 
69.3 99.3 74.4 
       
Placental 
Abruption 
64120 
64121 
64123 
64120 
64121 
64123 
Identification of placental abruption 
as ascertained through chart review 
by experienced accredited record 
technicians or certified coding 
specialists.83 
89.0 … 89.0 
       
Postpartum 
hemorrhage 
O72 O72 Identification of postpartum 
hemorrhage as ascertained through 
chart review by trained personnel.75 
90.2 98.2 … 
       
Chronic 
kidney 
disease 
* * * … … … 
       
 
Abbreviations: Sn, Sensitivity (indicates the percentage of women with the condition who are correctly identified as 
having the condition); Sp, Specificity (indicates the percentage of healthy women who are correctly identified as not 
having the condition); PPV, Positive predictive value (indicates the percentage of women whose diagnosis is recorded 
correctly). Ellipses indicate data not reported. 
*  Chronic kidney disease was defined using an algorithm of hospital diagnosis codes validated for older adults in the 
study region.78 This algorithm identified patients with a median estimated glomerular filtration rate of 38 
mL/min/1.73 m2 (interquartile range, 27 to 52 mL/min per 1.73 m2), whereas its absence identified patients with a 
median estimated glomerular filtration rate of 69 mL/min/1.73 m2 (interquartile range, 56 to 82 mL/min per 1.73 
m2).78 
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These coding algorithms were validated against a gold standard from chart review, which 
in many cases, was performed by a clinician using a well-described and accepted 
definition of the condition. These coding algorithms have high specificity and high 
positive predictive value. Sensitivity appears greatest for coding algorithms used to 
identify more severe disease. However, the operating characteristics reported in Table 7 
apply only to the coding algorithm specified and do not necessarily reflect the entire 
collection of codes used to define characteristics and outcomes in our study. Therefore, 
these statistics should only be used as a reference source from which the actual operating 
characteristics of coding algorithms used in this study can be approximated. Our rationale 
for including codes not previously validated was to improve sensitivity for capture of that 
variable.  
5.4 Population 
Ontario provides universal access to hospital and physician services for all permanent 
residents, with about 140,000 births per year over the previous 5 years (2009-2013).71 We 
established a cohort of all pregnancies resulting in childbirth between January 1, 1997, 
and December 31, 2011. Our data sources capture all hospital childbirths in the province, 
defined as delivery of an infant at a gestational age of ≥ 20 weeks.95,96  
We applied several data cleaning steps to ensure that (1) both maternal and perinatal data 
could be ascertained for each pregnancy, (2) all pregnancies were among live women of 
childbearing age, and (3) multiple gestations were not counted as more than one 
pregnancy.  
We assigned an index date to each pregnancy that was 42 weeks prior to delivery. This 
was used to define the onset of pregnancy and served as a reference point from which a 
lookback window for assessment of maternal and perinatal characteristics and an 
outcome assessment window could be defined. We used 42 weeks prior to delivery, the 
longest term gestational duration, for this purpose to avoid misclassification of conditions 
identified early in pregnancy as pre-pregnancy conditions. When relevant, the index date 
marked the onset of the first trimester, the index date plus 12 weeks (and 1 day) marked 
the onset of the second trimester, and the index date plus 27 weeks (and 1 day) marked 
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the onset of the third trimester. The postpartum period was defined by the 12 weeks after 
the delivery date.  
We then excluded pregnancies among mothers with a history of end-stage kidney disease 
(defined as chronic dialysis treatment or kidney transplantation) within 5 years prior to 
the index date as these women would already have experienced one of the maternal 
outcomes of interest prior to pregnancy. 
5.5 AKI-D 
We defined AKI-D as receipt of at least one acute dialysis treatment during pregnancy or 
within 12 weeks postpartum.  
5.6 Maternal Characteristics 
5.6.1 Maternal Characteristics Prior to Pregnancy 
We collected information on the following maternal characteristics at the time of 
delivery, assuming that this data would approximate status at the estimated beginning of 
pregnancy: age, neighborhood income quintile, and location of residence. We collected 
information on the following characteristics prior to pregnancy using a fixed lookback 
window of 5 years prior to the index date: number of previous pregnancies, time since 
previous pregnancy, presence of preexisting hypertension, diabetes mellitus, and chronic 
kidney disease, and previous physician visits with a general practitioner or family 
physician, internal medicine specialist, and nephrologist. This lookback window was 
fixed to avoid information bias based on cohort entry date.  
5.6.2 Maternal Complications During Pregnancy or the Postpartum 
Period 
We collected information on medical complications during pregnancy or within 12 weeks 
postpartum (complications such as preeclampsia may occur up to 12 weeks 
postpartum).97 These included multifetal gestation, hyperemesis gravidarum, gestational 
hypertension, preeclampsia, thrombotic microangiopathy, pyelonephritis, sepsis, 
caesarean delivery, and postpartum hemorrhage.  
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5.7 Perinatal Complications 
We collected data on the following perinatal complications at the time of delivery and up 
to (and including) 28 days after delivery: low birth weight (< 2500 g irrespective of 
gestational age), small for gestational age (birth weight < 10th percentile for gestational 
age), preterm birth (birth of a live infant before 37 weeks gestation), stillbirth (fetal death 
after 22 weeks gestation), perinatal mortality (stillbirth or death of a live-born infant 
within 7 days) and neonatal death (death of a live-born infant within 28 days).98–101 
5.8 Maternal Outcomes 
Maternal outcomes included (1) maternal death on or before 90 days after the date of 
delivery, and (2) chronic dialysis dependence, defined as the receipt of two or more 
chronic dialysis treatments between 90 and 120 days (17 weeks) after the date of delivery 
among survivors of AKI-D. 
5.9 Statistical analyses 
Pregnancy was the unit of analysis in this study. In order to evaluate the extent of within-
mother clustering, we first quantified the number of pregnancies resulting in childbirth 
during our accrual period and the number of unique mothers. 
We then determined the proportion of pregnancies affected by AKI-D during the accrual 
period (also referred to as the incidence proportion) and described the maternal 
characteristics prior to delivery in relation to AKI-D status. We used standardized 
differences to compare maternal characteristics in pregnancies with and without AKI-D. 
Standardized differences are less sensitive to sample size than traditional hypothesis tests 
and are not affected by clustering. They provide a measure of the difference between 
groups divided by the pooled standard deviation; a value of ≥ 0.10 (10%) is interpreted as 
a meaningful difference between groups.102 
We examined the association between maternal complications during pregnancy or the 
postpartum period and the incidence of AKI-D using generalized estimating equations 
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and log-binomial models to estimate the relative difference in the proportion of 
pregnancies affected by AKI-D among those with maternal complications compared to 
those without maternal complications, and reported the unadjusted incidence proportion 
ratios and 95% confidence intervals.  
We examined the association between AKI-D during pregnancy or the postpartum period 
and the incidence of perinatal complications similarly using generalized estimating 
equations and log-binomial models to estimate the relative difference in the proportion of 
pregnancies resulting in perinatal complications among those with AKI-D compared to 
those without AKI-D, and again reported the unadjusted incidence proportion ratios and 
95% confidence intervals. 
We then used generalized estimating equations and log-binomial models to estimate the 
relative difference in the risk of maternal death among those with AKI-D compared to 
those without AKI-D. We reported the proportion of pregnancies resulting in maternal 
death among those with and without AKI-D, the absolute risk difference, unadjusted 
relative risk with the 95% confidence interval, and the P value for the difference in 
unadjusted relative risk. We set the level of significance at P < 0.05.  
All analyses were unadjusted due to the small sample size in the AKI-D group, limited 
data to support assumptions about independence of maternal characteristics from the 
causal pathway between complications and maternal outcomes, and lack of sensitivity of 
our data sources for capture of these variables. We used log-binomial models to reflect 
the binomial distribution of outcomes with a log-link function to estimate incidence 
proportion ratios and relative risks.103 Generalized estimating equations were used to 
account for within-mother clustering from additional pregnancies during follow-up. This 
model assumes that clusters are independent and that the correlation matrix that 
represents the within-subject dependencies is estimated as part of the model (which in 
this case, assumes that the correlation is the same for all pregnancies that share the same 
mother, regardless of birth sequence).104 This model is ideal for analyses of many small 
clusters and is robust even if the working correlation structure is misspecified.87  
All analyses were conducted using SAS, version 9.3 (SAS Institute Inc., Cary, NC).  
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Chapter 7  
7 Discussion 
7.1 Main Findings 
In this study of 1.9 million pregnancies over a 15-year period, 1 in 10,000 pregnancies 
were affected by AKI-D. Most women who developed AKI-D had no record of a 
preexisting chronic medical condition such as hypertension, diabetes, or chronic kidney 
disease. Several maternal complications were associated with a higher incidence of AKI-
D in pregnancy or the postpartum period. These included preeclampsia, thrombotic 
microangiopathy, pyelonephritis, sepsis, caesarean delivery, and postpartum hemorrhage. 
AKI was associated with a higher incidence of adverse perinatal complications including 
low birth weight, small for gestational age, and preterm birth, however there were no 
stillbirths and no more than five neonatal deaths (< 3%) in affected pregnancies. Maternal 
mortality after AKI-D was 4%, and 4% of survivors remained dependent on dialysis after 
delivery. 
7.2 Comparison with Other Studies 
7.2.1 Incidence of AKI-D 
Most population-based reports on pregnancy-related AKI refer exclusively to secular 
trends in infection-related first-trimester AKI, coinciding with the legalization of abortion 
and improved obstetrical care in low-income countries.1,52–55 Pregnancies in high-income 
regions are more frequently complicated by hypertensive disorders of pregnancy, 
gestational diabetes, and postpartum hemorrhage, whereas genitourinary and obstetric 
infections appear to be on the decline.7 More recent North American studies examining 
the impact of these trends on AKI defined by hospital diagnosis codes, indicate a 
paradoxical increase in the incidence of AKI in pregnancy from what was previously 
reported, with an incidence proportion of approximately 2 in 10,000 deliveries.39,40,56 This 
trend has been attributed to the increasing incidence of hypertensive disorders of 
pregnancy in these populations.56 While AKI-D occurred much less frequently in our 
population (1 in 10,000 deliveries), our data suggest that these complications, alone or in 
36 
 
combination with other risk factors, may occur in a setting necessitating acute dialysis as 
well. 
7.2.2 Maternal Complications Associated with AKI-D 
Trends indicating an increasing incidence of AKI in North America appear to correspond 
to increases in the rate of deliveries among women at advanced maternal age or with pre-
existing medical conditions such as hypertension, diabetes mellitus, and chronic kidney 
disease (known risk factors for preeclampsia)59,60 and those with complications such as 
preeclampsia and postpartum hemorrhage noted in other population-based studies.7 
These, and other complications including sepsis, cardiac failure, and caesarean section 
have been confirmed to be associated with AKI in pregnancy, however the temporal 
increase in AKI in pregnancy reported in previous North American studies appears to be 
restricted to pregnancies complicated by hypertensive disorders, and was especially 
pronounced among women with preeclampsia.56 
Women who developed AKI-D in our cohort were generally healthy with few recorded 
pre-existing medical conditions. However, as the prevalence of preexisting medical 
conditions in our study was likely underestimated, women with chronic hypertension and 
preexisting chronic kidney disease may drive a greater proportion of AKI-D events than 
realized herein.7,8 In addition to preeclampsia, we identified several other maternal 
characteristics that alone or in combination may be associated with an increased 
incidence of AKI-D. These include thrombotic microangiopathy, pyelonephritis, sepsis, 
caesarean delivery, and postpartum hemorrhage. While it was beyond the scope of this 
research to determine the nature of these associations, many of these complications have 
been highlighted as associative factors in previous studies and could be assumed to be 
either directly causal of AKI (eg. preeclampsia, thrombotic microangiopathy, 
pyelonephritis, sepsis, postpartum hemorrhage) or occur as a result of the AKI episode or 
its complications (eg. caesarean delivery), based on known pathophysiologic mechanisms 
of AKI.38,56,69 
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7.2.3 Perinatal Complications of AKI-D 
No prior studies have assessed the incidence of perinatal complications in relation to 
pregnancy-related AKI; therefore it is unclear whether associated perinatal complications 
such as low birth weight, small for gestational age, and preterm birth may be attributed to 
the AKI-D event itself or to associated acute medical complications. Further, it is 
impossible to separate out the effect of AKI from the dialysis treatment with our data. 
However, early delivery as a result of deteriorating maternal condition and altered 
uteroplacental hemodynamics could explain this finding in either case.105 
7.2.4 Maternal Outcomes of AKI-D 
Recent reports of severe cases of pregnancy-related AKI are limited to two small studies 
from Brazil and Egypt, in which AKI was defined by treatment with dialysis and RIFLE 
criteria within admission to the intensive care unit respectively.38,69 These studies suggest 
that maternal mortality may be as high as 30% in more severe cases of AKI, with up to 
50% of women remaining dependent on dialysis after delivery.38,69 In contrast to these 
studies, our data suggest that although AKI events during pregnancy do occur more 
frequently in the context of acute medical complications, the impact may be short-lived. 
Maternal mortality in our study was only 4.3% (compared with 0.01% in the general 
population) and fewer than 4% of survivors were dependent on dialysis after 12 weeks 
postpartum. Accounting for differences in severity of AKI, this is in keeping with the 
2.8% incidence proportion of maternal death reported in previous population-based 
studies of AKI in pregnancy in Canada.56 However, dialysis dependence was not assessed 
in these studies.  
Although our results support a strong association between AKI-D and maternal mortality, 
the absolute risk of death is low. This, and the low proportion of survivors remaining 
dialysis dependent, should be viewed as reassuring when considering the overall impact 
of AKI-D on the population. Interpretation of the relative differences in risk of maternal 
mortality in this setting would require further exploration of the causal association 
between AKI-D and mortality, which was beyond the scope of this study.  
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7.3 Strengths  
The lack of a consensus definition for AKI in pregnancy and variations in demographics 
and standard of care among populations has made estimation of the current incidence of 
pregnancy-related AKI from epidemiologic studies difficult.1,39,40,52–56 Efforts to examine 
the maternal and perinatal complications in relation to pregnancy-related AKI in  
contemporary population-based cohorts is limited.39,40,56 To our knowledge, this is the 
first population-based study to characterize the incidence of AKI-D in pregnancy and its 
correlates and outcomes in a developed nation without apparent selection bias or loss to 
follow-up, containing over three times the number of cases treated with dialysis as in 
other reports.69 We were able to do this by using novel linkages between maternal and 
infant administrative data. 
7.4 Limitations 
The limitations of this study are outlined below. 
7.4.1 Generalizability 
The definition of AKI was restricted to those treated with dialysis, so these results may 
not apply to less severe presentations of AKI in pregnancy. Further, because the analytic 
cohort was limited to pregnancies that resulted in a live birth or stillbirth after 20 weeks 
gestation, study results are not generalizable to pregnancies resulting in an early 
pregnancy loss.  
7.4.2 Information Bias 
The presence and strength of associations observed in epidemiologic studies are a 
function of the validity of study variables. We conducted our analysis using hospital 
diagnostic and physician billing codes from administrative data. Our strategy for 
identifying many of the maternal indicators with these codes may lack sensitivity and, 
therefore, underestimate their true prevalence. In most cases, misclassification of these 
variables is expected to be non-differential as it is independent of AKI-D status and 
would be expected to bias measures of association between the presence (vs. absence) of 
these characteristics and incidence of AKI-D towards the null hypothesis (Type II 
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error).84 Although some coding algorithms may also lack specificity. For example, codes 
used to ascertain ‘thrombotic microangiopathy’ may capture cases of preeclampsia and 
HELLP syndrome, in addition to thrombotic thrombocytopenic purpura, given the lack of 
specificity of both the terminology and codes.  
Assuming a 42-week gestation for the purposes of defining the onset of pregnancy may 
have contributed to misclassification of pre-pregnancy maternal characteristics as 
pregnancy-related complications for preterm deliveries. However, most maternal 
characteristics ascertained during pregnancy are complications (and codes) specific to 
pregnancy (eg. multifetal gestation, hyperemesis gravidarum, gestational hypertension, 
preeclampsia, thrombotic microangiopathy) or would be expected to preclude conception 
of a viable pregnancy (eg. thrombotic microangiopathy, pyelonephritis, sepsis). 
Therefore, this misclassification should be limited. 
Additional sources of information bias include lack of access to clinical parameters at the 
time of dialysis initiation, including renal function, blood pressure, and basis for starting 
or stopping dialysis, so women with progressive chronic kidney disease initiating dialysis 
electively during pregnancy to optimize maternal and fetal wellbeing could have been 
misclassified as having AKI-D in this study. However, the low prevalence of preexisting 
chronic kidney disease and low proportion of women that remained dialysis dependent 
postpartum suggests that this was infrequent. Further, defining AKI by treatment with 
dialysis precludes our ability to isolate the independent effects of AKI from the dialysis 
treatment itself.  
7.4.3 Confounding 
There are several associations noted in this study that could be explored further. These 
include associations between various medical complications of pregnancy and the 
incidence of AKI-D, AKI-D and the incidence of various perinatal complications, and 
AKI-D and the risk of adverse maternal outcomes. However, as described in Section 3.3, 
the complex (and in many cases, causal) relationship between pre-pregnancy maternal 
characteristics, medical complications of pregnancy, perinatal complications, and adverse 
maternal outcomes precludes our ability to isolate potential confounders to incorporate 
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into multivariable logistic regression models to further explore these associations. 
Further, our study was underpowered for such analyses due to the low event rate of AKI-
D in our cohort and lack of sensitivity of coding algorithms used to ascertain maternal 
characteristics of interest. For this reason, results of these analyses should be viewed as 
hypothesis generating and confirmed in future studies.  
7.5 Recommendations for Future Research 
As a direct extension of this research, additional studies could be performed to confirm 
the independent association between several maternal characteristics in this study and the 
risk of AKI in pregnancy. However, there are several other knowledge gaps in this area 
that warrant further attention. Additional research is needed to establish a method of early 
and specific diagnosis of AKI in pregnancy, perhaps using renal biomarkers that are 
independent of serum creatinine, a late indicator of acute kidney injury in pregnancy.106 
Finally, although experience from treatment of pregnant women with end-stage renal 
disease suggests that intensified hemodialysis and frequent maternal and fetal 
surveillance might be the key to further improving maternal and perinatal outcomes in 
AKI settings as well, the threshold for initiation needs further consideration. 
Unfortunately, given the infrequency with which this condition occurs, it is unlikely there 
will ever be controlled trials in this area. Large observational studies using administrative 
data or a network meta-analysis, combining administrative data from multiple provinces, 
could be used to provide insight into this treatment decision.  
7.6 Conclusion 
This study confirms that AKI treated with dialysis in pregnancy is rare and typically 
occurs in otherwise healthy women who acquire a major pregnancy-related medical 
condition. While assessment for comorbid conditions such as hypertension, diabetes, and 
chronic kidney disease, remains central to identifying women at risk for hypertensive 
disorders of pregnancy, our data suggest that severe AKI may be occurring through a 
variety of physiologic mechanisms that may not be predictable from pre-pregnancy 
health status. Fortunately, with ongoing improvements in obstetrical care, 
multidisciplinary approaches, and new insights into the diagnosis and management of 
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associated conditions such as preeclampsia, maternal and perinatal mortality in this 
setting are largely avoidable. Knowledge of associated characteristics and outcomes 
presented in this study provide important prognostic information for patients and a 
framework for physicians to understand severe pregnancy-related AKI in the current era 
and inform strategies that better identify women at risk. 
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• Mean (SD) 
• Median (25th, 75th percentile) 
• Range (Min – Max) 
6. Hypertension, within 5 years prior to index date 
7. Diabetes mellitus, within 5 years prior to index date 
8. Chronic kidney disease, within 5 years prior to index date 
9. General practitioner/family physician consultation, within 5 years prior to index 
date 
10. Internal medicine specialist consultation, within 5 years prior to index date 
11. Nephrologist consultation, within 5 years prior to index date 
 
Maternal Characteristics During Pregnancy or the Postpartum Period 
To be determined between the index date and 12 weeks after delivery date. 
1. Multifetal gestation, defined by [m_multiple birth=T or b_multiple birth=T] in 
mother or infant record in MOMBABY dataset. All other pregnancies are 
assumed to be singletons. 
2. Hyperemesis gravidarum 
3. Gestational hypertension 
4. Preeclampisa 
5. Thrombotic microangiopathy 
6. History of thrombotic microangiopathy (TMA) requiring plasma exchange, 
defined by any of the following: 
a) The receipt of PLEX (by OHIP fee codes) that falls within an admission for 
TMA (using CIHI codes) 
b) The receipt of PLEX (by OHIP fee codes) that is preceded by a TMA code 
(using OHIP dx codes) within 7 days. Use the PLEX code that is closest to 
the TMA code to define this interval. 
c) The receipt of PLEX (by OHIP fee codes) that is preceded by a TMA code 
(using OHIP dx codes) within 7 days. Use the PLEX code that is closest to 
the TMA code to define this interval. 
6. Pyelonephritis 
7. Sepsis 
8. Caesarean delivery 
9. Postpartum hemorrhage 
 
Perinatal Characteristics 
Differences in infant birthdate exist between MOMBABY and RPDB – selected 
MOMBABY to define infant birthdate given many missing b_ikns required to link to 
RPDB 
1. Low birthweight: Defined by a weight of less than 2500g for the variable 
[WEIGHT] in the infant record (b_key) in the MOMBABY/CIHI dataset. Assess 
on delivery date 
Look at data carefully, as may need to troubleshoot errors in data entry 
(kilograms vs. grams): a ‘0’ preceding the number (eg. 0900) implies that weight 
reported in kilograms (eg. 90.0 kg), however many of these values may in fact 
be reported in grams (eg. 900g). If value ≥ 0100, interpret as grams (eg. 100g). If 
value <0100, interpret as kilograms (eg. 10.0 kg) and use 0001 as the lowest 
possible birthweight allowed (eg. 0.1 kg or 100g). 
2. Small for gestational age/Intrauterine growth restriction: Defined by codes in the 
m_ikn, b_ikn, or b_key. Assess from delivery date to 12 weeks after the index 
date 
3. Premature birth: Defined as birth before 37 weeks of gestation using 
[m_gestwks_del and b_gestwks_del] in mother and infant record in 
MOMBABY dataset respectively where [b_stillbirth=F and m_stillbirth=F] or 
the presence of a Prematurity/LowBirthweight code. Preferentially use infant 
data source unless it is missing, in which case use mother data source. The 
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absence) of AKI-D. Report the risk difference with 95% confidence 
interval and the unadjusted relative risk with 95% confidence interval and 
P-value.  
• Report the proportion of pregnancies in the AKI-D group that fulfilled the 
maternal outcome definition of chronic dialysis dependence. 
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